Omar N Pathmanaban1,2, Katherine V Sadler3,4, Ian D Kamaly-Asl2,5, Andrew T King1, Scott A Rutherford1, Charlotte Hammerbeck-Ward1, Martin G McCabe2,5, John-Paul Kilday2,5, Christian Beetz6, Nicola K Poplawski7, D Gareth Evans3,4, Miriam J Smith3,4. 1. Department of Neurosurgery, Manchester Centre for Clinical Neuroscience, Salford Royal National Health Service Foundation Trust, Manchester Academic Health Science Centre, University of Manchester, Manchester, England. 2. Children's Brain Tumour Research Network, Royal Manchester Children's Hospital, Centre for Paediatric, Teenage, and Young Adult Cancer, University of Manchester, Manchester, England. 3. Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, England. 4. Manchester Centre for Genomic Medicine, St Mary's Hospital, Central Manchester University Hospitals National Health Service Foundation Trust and Manchester Academic Health Science Centre, Manchester, England. 5. Division of Molecular and Clinical Cancer Sciences, School of Medical Science, Faculty of Biology, Medicine, and Health, Manchester Academic Health Science Centre, Manchester, England. 6. Institut für Klinische Chemie und Laboratoriumsdiagnostik, Universitätsklinikum Jena, Jena, Germany. 7. Adult Genetics Unit, South Australia Pathology at the Women's and Children's Hospital, and University Department of Paediatrics, University of Adelaide, Adelaide, Australia.
Abstract
Importance: Meningiomas and schwannomas are usually sporadic, isolated tumors occurring in adults older than 60 years and are rare in children and young adults. Multiple schwannomas and/or meningiomas are more frequently associated with a tumor suppressor syndrome and, accordingly, trigger genetic testing, whereas solitary tumors do not. Nevertheless, apparently sporadic tumors in young patients may herald a genetic syndrome. Objective: To determine the frequency of the known heritable meningioma- or schwannoma-predisposing mutations in children and young adults presenting with a solitary meningioma or schwannoma. Design, Setting, and Participants: Using the database of the Manchester Centre for Genomic Medicine, this cohort study analyzed lymphocyte DNA from young individuals prospectively referred to the clinic for genetic testing between January 1, 1990, and December 31, 2016, on presentation with a single meningioma (n = 42) or schwannoma (n = 135) before age 25 years. Sequencing data were also examined from an additional 39 patients with neurofibromatosis type 2 who were retrospectively identified as having a solitary tumor before age 25 years. Patients with schwannoma were screened for NF2, SMARCB1, and LZTR1 gene mutations, while patients with meningioma were screened for NF2, SMARCB1, SMARCE1, and SUFU. Main Outcomes and Measures: The type of underlying genetic mutation, or lack of a predisposing mutation, was associated with the presenting tumor type and subsequent development of additional tumors or other features of known schwannoma- and meningioma-predisposing syndromes. Results: In 2 cohorts of patients who presented with an isolated meningioma (n = 42; median [range] age, 11 [1-24] years; 22 female) or schwannoma (n = 135; median [range] age, 18 [0.2-24] years; 60 female) before age 25 years, 16 of 42 patients (38%) had a predisposing mutation to meningioma and 27 of 135 patients (20%) to schwannoma, respectively. In the solitary meningioma cohort, 34 of 63 patients (54%) had a constitutional mutation in a known meningioma predisposition gene. Twenty-five of 63 patients (40%) had a constitutional NF2 mutation, and 9 (14%) had a constitutional SMARCE1 mutation. In the cohort of those who developed a solitary schwannoma before age 25 years, 44 of 153 patients (29%) had an identifiable genetic predisposition. Twenty-four patients (55%) with a spinal schwannoma had a constitutional mutation, while only 20 (18%) with a cranial schwannoma had a constitutional predisposition (P < .001). Of 109 cranial schwannomas, 106 (97.2%) were vestibular. Four of 106 people (3.8%) with a cranial schwannoma had an LZTR1 mutation (3 were vestibular schwannomas and 1 was a nonvestibular schwannoma), and 9 (8.5%) had an NF2 mutation. Conclusions and Relevance: A significant proportion of young people with an apparently sporadic solitary meningioma or schwannoma had a causative predisposition mutation. This finding has important clinical implications because of the risk of additional tumors and the possibility of familial disease. Young patients presenting with a solitary meningioma or schwannoma should be referred for genetic testing.
Importance: Meningiomas and schwannomas are usually sporadic, isolated tumors occurring in adults older than 60 years and are rare in children and young adults. Multiple schwannomas and/or meningiomas are more frequently associated with a tumor suppressor syndrome and, accordingly, trigger genetic testing, whereas solitary tumors do not. Nevertheless, apparently sporadic tumors in young patients may herald a genetic syndrome. Objective: To determine the frequency of the known heritable meningioma- or schwannoma-predisposing mutations in children and young adults presenting with a solitary meningioma or schwannoma. Design, Setting, and Participants: Using the database of the Manchester Centre for Genomic Medicine, this cohort study analyzed lymphocyte DNA from young individuals prospectively referred to the clinic for genetic testing between January 1, 1990, and December 31, 2016, on presentation with a single meningioma (n = 42) or schwannoma (n = 135) before age 25 years. Sequencing data were also examined from an additional 39 patients with neurofibromatosis type 2 who were retrospectively identified as having a solitary tumor before age 25 years. Patients with schwannoma were screened for NF2, SMARCB1, and LZTR1 gene mutations, while patients with meningioma were screened for NF2, SMARCB1, SMARCE1, and SUFU. Main Outcomes and Measures: The type of underlying genetic mutation, or lack of a predisposing mutation, was associated with the presenting tumor type and subsequent development of additional tumors or other features of known schwannoma- and meningioma-predisposing syndromes. Results: In 2 cohorts of patients who presented with an isolated meningioma (n = 42; median [range] age, 11 [1-24] years; 22 female) or schwannoma (n = 135; median [range] age, 18 [0.2-24] years; 60 female) before age 25 years, 16 of 42 patients (38%) had a predisposing mutation to meningioma and 27 of 135 patients (20%) to schwannoma, respectively. In the solitary meningioma cohort, 34 of 63 patients (54%) had a constitutional mutation in a known meningioma predisposition gene. Twenty-five of 63 patients (40%) had a constitutional NF2 mutation, and 9 (14%) had a constitutional SMARCE1 mutation. In the cohort of those who developed a solitary schwannoma before age 25 years, 44 of 153 patients (29%) had an identifiable genetic predisposition. Twenty-four patients (55%) with a spinal schwannoma had a constitutional mutation, while only 20 (18%) with a cranial schwannoma had a constitutional predisposition (P < .001). Of 109 cranial schwannomas, 106 (97.2%) were vestibular. Four of 106 people (3.8%) with a cranial schwannoma had an LZTR1 mutation (3 were vestibular schwannomas and 1 was a nonvestibular schwannoma), and 9 (8.5%) had an NF2 mutation. Conclusions and Relevance: A significant proportion of young people with an apparently sporadic solitary meningioma or schwannoma had a causative predisposition mutation. This finding has important clinical implications because of the risk of additional tumors and the possibility of familial disease. Young patients presenting with a solitary meningioma or schwannoma should be referred for genetic testing.
Authors: Miriam J Smith; Christian Beetz; Simon G Williams; Sanjeev S Bhaskar; James O'Sullivan; Beverley Anderson; Sarah B Daly; Jill E Urquhart; Zaynab Bholah; Deemesh Oudit; Edmund Cheesman; Anna Kelsey; Martin G McCabe; William G Newman; D Gareth R Evans Journal: J Clin Oncol Date: 2014-11-17 Impact factor: 44.544
Authors: I Christiaans; S B Kenter; H C Brink; T A M van Os; F Baas; P van den Munckhof; A M J Kidd; T J M Hulsebos Journal: J Med Genet Date: 2010-10-07 Impact factor: 6.318
Authors: D Gareth R Evans; R T Ramsden; A Shenton; C Gokhale; N L Bowers; S M Huson; G Pichert; A Wallace Journal: J Med Genet Date: 2007-02-16 Impact factor: 6.318
Authors: A Perry; C Giannini; R Raghavan; B W Scheithauer; R Banerjee; L Margraf; D C Bowers; R A Lytle; I F Newsham; D H Gutmann Journal: J Neuropathol Exp Neurol Date: 2001-10 Impact factor: 3.685
Authors: Cigall Kadoch; Diana C Hargreaves; Courtney Hodges; Laura Elias; Lena Ho; Jeff Ranish; Gerald R Crabtree Journal: Nat Genet Date: 2013-05-05 Impact factor: 38.330
Authors: Miriam J Smith; Naomi L Bowers; Michael Bulman; Carolyn Gokhale; Andrew J Wallace; Andrew T King; Simon K L Lloyd; Scott A Rutherford; Charlotte L Hammerbeck-Ward; Simon R Freeman; D Gareth Evans Journal: Neurology Date: 2016-11-16 Impact factor: 9.910
Authors: Miriam J Smith; Andrew J Wallace; Chris Bennett; Martin Hasselblatt; Ewelina Elert-Dobkowska; Linton T Evans; William F Hickey; Jack van Hoff; David Bauer; Amy Lee; Robert F Hevner; Christian Beetz; Daniel du Plessis; John-Paul Kilday; William G Newman; D Gareth Evans Journal: J Pathol Date: 2014-10-06 Impact factor: 7.996
Authors: Cathal J Hannan; Daniel Lewis; Claire O'Leary; Carmine A Donofrio; Dafydd G Evans; Emma Stapleton; Simon R Freeman; Simon K Lloyd; Scott A Rutherford; Charlotte Hammerbeck-Ward; David Brough; Stuart M Allan; David Coope; Andrew T King; Omar N Pathmanaban Journal: J Neurol Surg B Skull Base Date: 2020-09-10
Authors: Roland Goldbrunner; Michael Weller; Jean Regis; Morten Lund-Johansen; Pantelis Stavrinou; David Reuss; D Gareth Evans; Florence Lefranc; Kita Sallabanda; Andrea Falini; Patrick Axon; Olivier Sterkers; Laura Fariselli; Wolfgang Wick; Joerg-Christian Tonn Journal: Neuro Oncol Date: 2020-01-11 Impact factor: 12.300
Authors: D Gareth Evans; Andrew J Wallace; Claire Hartley; Simon R Freeman; Simon K Lloyd; Owen Thomas; Patrick Axon; Charlotte L Hammerbeck-Ward; Omar Pathmanaban; Scott A Rutherford; Mark Kellett; Roger Laitt; Andrew T King; Jemma Bischetsrieder; Jaishri Blakeley; Miriam J Smith Journal: Laryngoscope Date: 2018-10-16 Impact factor: 3.325
Authors: Maria Lucia Sur; Ionel Armat; Genel Sur; Diana-Cristina Pop; Gabriel Samasca; Iulia Lupan; Teodora-Larisa Timis; Ioan-Alexandru Florian; Daniel Sur Journal: Children (Basel) Date: 2022-01-02
Authors: M C Frühwald; K Nemes; H Boztug; M C A Cornips; D G Evans; R Farah; S Glentis; M Jorgensen; K Katsibardi; S Hirsch; K Jahnukainen; I Kventsel; K Kerl; C P Kratz; K W Pajtler; U Kordes; V Ridola; E Stutz; F Bourdeaut Journal: Fam Cancer Date: 2021-02-03 Impact factor: 2.375